Jump to content
RemedySpot.com

Ofatumumab + Btk inhibitor in relapsed CLL

Rate this topic

Guest guest

By Guest guest
in Health, Medicine and Natural Healing 10

 Share

Recommended Posts

Guest guest

Guest guest

Posted
Posted

A Phase 1b/2 Study of PCI-32765, a Btk-inhibitor, and Ofatumumab in Subjects

With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic

Lymphoma and Related Diseases

http://bit.ly/eDSJaf

Ofatumumab is an antibody therapy that targets a unique portion of the cd20

molecule - and is approved for CLL.

info http://www.ncbi.nlm.nih.gov/pubmed/18390837

Btk inhibitors target the BCR signaling pathway in b-cell malignancies - the

Btk component of that system.

info:

http://www.pharmacyclics.com/pdf/ASCO_2010_Pharmacyclics_BTK_Inhibitor_PCI-3

2765.pdf

Karl

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
 Share
Go to topic listing
×
×
  • Create New...